SCHEMBL21789944

SCHEMBL21789944

CNc1nc(Br)ccc1C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.34
CYP2C19 P33261 3/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
CYP1A2 P05177 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CYP2D6 P10635 2/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
IKBKB O14920 1/20 0.31
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30
LRRK2 Q5S007 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2674300 0.77 GAA (0.36) HTTGAA
SCHEMBL13547616 0.76 CCR1 (0.40) CYP3A4CYP2C19KDM4EALDH1A1HPGD
SCHEMBL5292836 0.76 HTR6 (0.33) KDM4EMAPT
SCHEMBL18132265 0.76 IDO1 (0.33) ALDH1A1MAPTALOX15
SCHEMBL31731416 0.76 HTR6 (0.33) KDM4EMAPT
SCHEMBL23213865 0.75 GLO1 (0.40) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL29844539 0.75 GLO1 (0.40) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL5631598 0.74 NCF1 (0.45) CYP3A4CYP2C19KDM4EALDH1A1HPGD
SCHEMBL27446083 0.74 CYP1A2 (0.42) ALDH1A1HTTCYP1A2TDP1CLK4
SCHEMBL23213942 0.74 ALDH1A1 (0.40) CYP3A4CYP2C19KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3985002-A1 ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS Achillion Pharmaceuticals, Inc. (US) 2022-04-20 EP disclosed
US-20200071301-A1 Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071301-A1 Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders CFD, TFPI, CFH CYP3A4 81/4885CYP2C19 43/4885KDM4E 3412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.